R-CHOP
R-CHOP 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Untreated Follicular Lymphoma。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
24 项
全球在招研究
8 项
已进入 III/IV 期
31 个
开展国家和地区
有
中国境内设点
药品与企业信息
研发企业
- AstraZeneca
- Dizal Pharmaceuticals
- Sun Yat-sen University
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Ruijin Hospital
- Ain Shams University
- Jennifer Crombie, MD
- Celgene
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
中国、Egypt、美国、澳大利亚、Brazil、加拿大、Chile、芬兰、法国、德国、Greece、India
正在招募患者的 R-CHOP 研究
DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12)
I 期 / II 期招募中中国NCT07059650Safety and Efficacy of R-CMOP Versus R-CHOP in the Initial Treatment of DLBCL
I 期 / II 期招募中中国NCT06760039Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma
I 期 / II 期招募中中国NCT06829771The Safety and Effectiveness of 4R-CHOP+4R vs 6R-CHOP+2R in Newly Diagnosed Patients With DLBCL in Low Risk
III 期招募中中国NCT05018520A Study of Trilaciclib Combined With Chemotherapy in the Treatment of Diffuse Large B-Cell Lymphoma Patients
II 期招募中中国NCT06569485Predictive Value of CRP, Albumin, CAR, and mGPS in Treatment Outcomes of DLBCL
不适用招募中EgyptNCT07057765A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma
II 期招募中美国NCT05800366A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
III 期招募中美国澳大利亚Brazil加拿大NCT06911502Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma
III 期招募中中国NCT06520163A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
III 期招募中美国澳大利亚奥地利比利时NCT06091865A Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma
II 期招募中美国NCT03758989Celecoxib Plus R-CHOP vs R-CHOP in Newly Diagnosed Advanced CD5+ DLBCL
II 期招募中中国NCT07494565Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
II 期招募中美国NCT04002947AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL
III 期招募中澳大利亚比利时Brazil加拿大NCT07215585Chidamide Plus R-CHOP in Newly Diagnosed Double-Expressor Diffuse Large B-Cell Lymphoma With Other Molecular Subtypes
II 期招募中中国NCT06891157A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
III 期招募中美国Argentina澳大利亚比利时NCT06717347AZA Combined With RCHOP in P53-mutated DLBCL.
II 期招募中中国NCT06158399Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas
I 期招募中美国NCT07278856Sintilimab Plus Rituximab Followed by R-CHOP Regimen in Untreated PMBL
II 期招募中中国NCT06742502Radiation Dose Optimization in Diffuse Large B- Cell Lymphoma.
不适用招募中IndiaNCT02964858Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell Lymphoma
III 期招募中德国NCT05820841A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma
III 期招募中澳大利亚丹麦芬兰意大利NCT04332822Cognitive Impairment in Patients With Diffuse Large B-Cell Lymphoma
不适用招募中SloveniaNCT07443514Loncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL)
I 期招募中美国NCT06977711
中国患者怎么争取用上这款药
这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。
查看完整申请指南本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。